Proteome Sciences (LSE:PRM) Debt-to-Equity : -2.59 (As of Jun. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Proteome Sciences Debt-to-Equity?

Proteome Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £12.55 Mil. Proteome Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £1.07 Mil. Proteome Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2024 was £-5.27 Mil. Proteome Sciences's debt to equity for the quarter that ended in Jun. 2024 was -2.59.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Proteome Sciences's Debt-to-Equity or its related term are showing as below:

LSE:PRM' s Debt-to-Equity Range Over the Past 10 Years
Min: -48.07 Med: -3.5 Max: 176.94
Current: -2.59

During the past 13 years, the highest Debt-to-Equity Ratio of Proteome Sciences was 176.94. The lowest was -48.07. And the median was -3.50.

LSE:PRM's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.27 vs LSE:PRM: -2.59

Proteome Sciences Debt-to-Equity Historical Data

The historical data trend for Proteome Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteome Sciences Debt-to-Equity Chart

Proteome Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-2.97

-3.29

-4.21

-14.13

-4.40

Proteome Sciences Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															-4.59	-14.13	-8.18	-4.40	-2.59

Competitive Comparison of Proteome Sciences's Debt-to-Equity

For the Diagnostics & Research subindustry, Proteome Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteome Sciences's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's Debt-to-Equity falls into.

Proteome Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Proteome Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.844	+	1.631)	/	-3.066
	=	-4.39

Proteome Sciences's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.548	+	1.073)	/	-5.266
	=	-2.59

Proteome Sciences (LSE:PRM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Proteome Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Proteome Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteome Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Proteome Sciences PLC (LSE:PRM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PMSNF:USA PRM.GB:UK

Address

Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP

Website

https://www.proteomics.com

Proteome Sciences PLC is protein biomarker research and development. provider of contract research services for the identification, validation and application of protein biomarkers. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Other.